A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined With Daratumumab in Participants With Advanced or Metastatic Solid Tumors

The purpose of this study is to determine whether a combination of Nivolumab and Daratumumab is safe and effective when treating Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, that have advanced or have spread.

Inclusion Criteria:

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

• Patients with metastatic or advanced solid tumors
• Women with histologically or cytologically confirmed triple negative breast carcinoma
• Participants with histologically or cytologically confirmed pancreatic adenocarcinoma
• Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer (NSCLC)

Exclusion Criteria:

• Active brain metastases or leptomeningeal metastases.
• Any serious or uncontrolled medical disorder
• Prior malignancy active within the previous 3 years

Other protocol defined inclusion/exclusion criteria could apply